Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):782-6. doi: 10.1002/pds.1617.

The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.

Author information

1
Duke Translational Medicine Institute, Durham, NC 27715, USA. robert.califf@duke.edu
PMID:
18655016
DOI:
10.1002/pds.1617
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center